To investigate the effect of prostatic fibroblasts on the survival of prostate cancer cells on treatment with chemotherapeutic drugs, wild-type TP53-carrying LNCaP prostate cancer cells were co-cultured in a transwell system under physical separation with cancer-associated fibroblasts (CAFs) or normal fibroblasts (NFs) from patients (cancer cell-fibroblast ratio 2:1). This evidence concerns the gene TP53 and cancer.